Novo Nordisk’s Pipeline Progress and Pill Milestone Fail to Budge Stock From 46% Below High

Despite a 46.86% drop from its 52-week high, Novo Nordisk reports strong Wegovy pill uptake, promising clinical data, and Medicare expansion. Investors remain indifferent.

Novo Nordisk closed the week at €37.27, a level that leaves the Danish drugmaker trading 46.86% below its 52-week peak of €70.13 set in June 2025. The stock has recovered from a low of €30.25, but the technical picture remains tepid: the relative strength index stands at 48.3, the shares sit just 4.11% above their 50-day moving average and roughly 10.5% beneath the 200-day line. For a company that just announced a rapid-fire series of commercial and clinical wins at the American Diabetes Association meeting in New Orleans, the market’s indifference is striking.

That commercial win is the Wegovy pill. Since launching in U.S. pharmacies and online channels in January, the oral formulation has racked up three million prescriptions in just over five months. The first million came in twelve weeks; the next two million followed in only ten. Crucially, more than 80% of those new scripts went to patients who had never used a GLP-1 therapy before — a sign that the tablet is expanding the addressable obesity market rather than cannibalising the injectable Wegovy franchise. The pill’s international rollout began on 3 June with the 25 mg dose hitting pharmacies in the United Arab Emirates, the first market outside the U.S. Further launches are slated for the second half of 2026.

On the clinical front, Novo Nordisk brought a full pipeline briefing to ADA. On 7 June it unveiled the complete phase 3 results from the REIMAGINE-1-2-3 studies of CagriSema, a combination of an amylin analogue and a GLP-1 agonist. The drug met its primary and secondary endpoints, delivering significant reductions in HbA1c and body weight in type 2 diabetes patients. The data were simultaneously published in The Lancet Diabetes & Endocrinology. Two days earlier, phase 2 data for Zenagamtide (Amycretin) showed that up to 89.1% of participants achieved an A1C below 7%, while those on the highest dose lost up to 14.6% of their body weight after 36 weeks. Phase 3 development for Zenagamtide is set to begin in the second half of 2026.

CEO Mike Doustdar used the ADA stage to sketch a broader strategic vision. He said the company is actively exploring GLP-1 applications in longevity research and aesthetic medicine, building on the organ-protective properties of semaglutide. The message is that Novo Nordisk has at least two promising follow-up candidates beyond semaglutide, and that it intends to push into entirely new therapeutic categories.

Yet the near-term catalyst that investors are watching most closely is the Medicare GLP-1 Bridge program, which goes live on 1 July 2026. Eligible Medicare beneficiaries with obesity will gain access to both injectable and oral Wegovy for a flat $50 monthly copay. The program was originally set to expire at the end of 2026 but has been extended through the end of 2027, giving Novo Nordisk more runway to convert beneficiaries into long-term patients. The drugmaker and Eli Lilly have agreed to supply their GLP-1 drugs to Medicare at a net price of $245 per month — far below list prices exceeding $1,000. Doustdar has set a target of roughly 15 million additional patients but acknowledges that access will not open fully overnight.

In the background, Novo Nordisk is executing a share buyback. A tranche launched in May covers up to 11.2 billion Danish kroner as part of a broader 15-billion-kroner repurchase framework. The next major dates on the calendar are the half-year results on 5 August 2026, followed by a capital markets day on 21 September. Until then, the company must persuade the market that its combination of pipeline depth, rapid pill uptake, and expanded Medicare access can translate into a sustainable growth story — and finally lift the stock out of its deep trough.